Gruppo di Ricerca GISSI Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2002
NCT00336336
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

polyunsaturated fatty acids (1 trial)

rosuvastatin (crestor) (1 trial)

valsartan (diovan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 3)

Heart Failure (Phase 3)

Recurrence (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3